SCHEMBL1521607

SCHEMBL1521607

Cc1cc(F)c(NC(=O)Nc2cnn(C(C)(C)C)c2)cc1N1Cc2cnc(NCCN(C)C)cc2N(C)C1=O

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNK2 Q07912 8/20 0.33
MAP4K2 Q12851 8/20 0.33
KDR P35968 4/20 0.32
FGFR1 P11362 2/20 0.32
BRAF P15056 4/20 0.32
WNT1 P04628 1/20 0.31
CLK2 P49760 1/20 0.31
CLK3 P49761 1/20 0.31
GSK3B P49841 1/20 0.31
DYRK1A Q13627 1/20 0.31
BMX P51813 5/20 0.31
ABL1 P00519 2/20 0.31
LCK P06239 1/20 0.31
FES P07332 1/20 0.31
RET P07949 1/20 0.31
PDGFRB P09619 1/20 0.31
KIT P10721 1/20 0.31
SRC P12931 1/20 0.31
PDGFRA P16234 1/20 0.31
FLT1 P17948 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1521629 0.89 RAF1 (0.36) TNK2MAP4K2KDRFGFR1BRAF
SCHEMBL4571153 0.84 MAPK8 (0.31) KDRFGFR1MAPK8MAPK9MAPK10
SCHEMBL1522011 0.82 NEK7 (0.35) TNK2MAP4K2KDRFGFR1BRAF
SCHEMBL1521841 0.80 RAF1 (0.36) KDRFGFR1BRAFABL1KIT
SCHEMBL1521511 0.80 BRAF (0.35) TNK2MAP4K2KDRFGFR1BRAF
SCHEMBL1521411 0.78 FGFR4 (0.35) TNK2MAP4K2KDRFGFR1WNT1
SCHEMBL1521380 0.77 KDR (0.36) KDRFGFR1BRAFKITPDGFRA
SCHEMBL1521700 0.77 RAF1 (0.37) TNK2MAP4K2KDRFGFR1BRAF
SCHEMBL5061725 0.76 BRAF (0.48) KDRFGFR1BRAFABL1KIT
SCHEMBL1521543 0.75 RAF1 (0.37) TNK2MAP4K2KDRFGFR1BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 US claimed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 US claimed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 US claimed
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 US disclosed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 US disclosed
EP-2063896-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Deciphera Pharmaceuticals, LLC. (US) 2009-06-03 EP disclosed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 US disclosed
WO-2008033999-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases BRAF, PRKDC, RAF1 TNK2 119/4885MAP4K2 22/4885KDR 500/4885
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 TNK2 119/4885MAP4K2 22/4885KDR 500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.